Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Non-Current Liabilities (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $197000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed 0.0% to $197000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $197000.0, a 0.0% change, with the full-year FY2025 number at $197000.0, changed 0.0% from a year prior.
  • Other Non-Current Liabilities was $197000.0 for Q4 2025 at Fulcrum Therapeutics, roughly flat from $197000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $447000.0 in Q2 2023 to a low of $197000.0 in Q2 2022.
  • A 4-year average of $221866.7 and a median of $197000.0 in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: surged 126.9% in 2023, then plummeted 55.93% in 2024.
  • Fulcrum Therapeutics' Other Non-Current Liabilities stood at $197000.0 in 2022, then changed by 0.0% to $197000.0 in 2023, then changed by 0.0% to $197000.0 in 2024, then changed by 0.0% to $197000.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Other Non-Current Liabilities are $197000.0 (Q4 2025), $197000.0 (Q3 2025), and $197000.0 (Q2 2025).